Company Overview and News
KUALA LUMPUR: The Malaysian stock market suffered yet another day of losses as the FBM KLCI fell 17.43 points or 1.02% to close at 1,692.32 points, below the 1,700 level for the first time since March 2017.
6399 AMMHF 5168 5014 7277 KLKBY 2445 1015 4863 5347 TNABY 6888 MYPRY AXXTF MYTEF TNABF GEBHF HRGHY
KUALA LUMPUR (June 21): The FBM KLCI fell 1.08% at the midday break today, dragged by losses at index-linked telecommunications and banking stocks.
HLFBF PBLOF 4065 1082 BATS 4162 2291 AMMHF 7765 1295 7077 KLKBY 2445 1015 4863 5347 TNABY 6888 5819 AXXTF MYTEF TNABF GEBHF 3719
SINGAPORE, June 20 — Indonesian shares slumped 2.5 per cent day, their sharpest intraday fall in nearly two months, after trade resumed following a long holiday for Eid Al-Fitr celebrations.
6888 AXXTF GEBHF
KUALA LUMPUR (June 20): The FBM KLCI snapped its losing streak and rose in early trade this morning, tracking the rebound at most regional markets.
HLFBF PBLOF MLYBY MLYNF UPBMF 1082 7113 TPGVF 1295 2089 5014 TGLVY 1155 MYPRY GEBHF
KUALA LUMPUR (June 18): The FBM KLCI fell 1.07% at mid-morning today as regional markets spooked by the escalating US-China trade spat mostly retreated.
PBLOF 7251 5183 PECGF 7060 UPBMF 4065 5681 2291 1163 1295 2089 5014 KLKBY 2445 5347 3301 1996 TNABY 5819 MYPRY TNABF GEBHF
KUALA LUMPUR (June 14): The FBM KLCI narrowed its losses at market close today, but remained in the red in line with its regional peers, dragged by losses at Genting-related stocks and CIMB Group Holdings Bhd.
7251 MLYNF 5197 BATS 4162 GMALY 0133 1023 4715 PNAGF GEBHF HRGHY MLYBY SPMXF GMALF 5681 SNHHF 6432 5168 6033 CIMDF 5139 1155 PNADF SPMXY 0900 BSMAF 1818
KUALA LUMPUR (June 12): The FBM KLCI fell 11.64 points or 0.7% while the ringgit weakened as investors anticipated major central banks' monetary policies this week. At 5pm, the KLCI finished at 1,764.16 points after the ringgit depreciated to its weakest level today against the US dollar at 3.9940.
TGLVY 7113 8664 TPGVF BATS 4162 GEBHF
KUALA LUMPUR (June 12): The FBM KLCI fell 0.38% at the midday break today against the backdrop of choppy regional markets, dragged by select index-linked blue chips.
HLFBF 7251 MLYBY MLYNF UPBMF 1082 7113 5032 8664 TPGVF BATS 4162 2089 9334 2852 TGLVY 1155 0047 5347 3301 TNABY TNABF GEBHF
KUALA LUMPUR: Bursa Malaysia recorded the highest ever in trading value on Thursday at more than RM9bil as the FBM KLCI staged a steady rebound as the government unveiled more solid measures to strengthen the economy. At 5pm, the KLCI was up 21.34 points or 1.24% to 1,740.62. However, it managed to only recoup more than just one-third of the losses after falling more 56 points the previous day in a broad selloff.
PBLOF GMALF 4065 4197 5681 1295 6033 GMALY PNADF 4715 SMEBF 8869 5819 BSMAF PNAGF GEBHF 1818
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK GS.PRICL GSC TFG GS.PRB GS.PRA GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC GJS GS.PRN GEBHF GS.PRK
KUALA LUMPUR: RAM Ratings sees Genting Bhd strengthening its competitive position and improving its performance after completing its RM10.4bil rejuvenation project for its second largest leisure and hospitality (L&H) contributor, Resorts World Genting (RWG).
KUALA LUMPUR: Foreign funds reacted to the unprecedented outcome of Malaysia’s General Election (GE14) by dumping RM2.48bil of local equities last week.
GMALY 5225 4715 GMALF 5681 Q0F IHHHF GEBHF
KUALA LUMPUR: Genting Bhd , Dagang NeXchange Bhd (DNeX), Malaysia Marine And Heavy Engineering Holdings Bhd (MHB), Axiata Group Bhd and Alam Maritim Resources Bhd are among the stocks to watch, according to JF Apex Research.
4502 4456 5115 3301 6888 MIAHF MALRY 5186 AXXTF MALRF MIN GEBHF
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET